Hemispherx Biopharma, Inc., a specialty pharmaceutical company, has extended its agreement with Armada Health Care, LLC, a specialty pharmacy group contracting and service organization, for two years (through August 14 2017) for the sales/marketing of Alferon N Injection, its US Food and Drug Administration approved natural interferon, in the US. Under the agreement, Hemisphere will manufacture and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies. Armada has agreed to provide ongoing sales and marketing to support the product's re-launch. The specialty distributor, BioRidge Pharma, LLC, has received a two-year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for US sales.

Source: Hemispherx Biopharma